Nirsevimab Library
This is a collection of current resources related to Nirsevimab.
Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024
2024
· Centers for Disease Control and Prevention (CDC),
· Vanderbilt University,
· Seattle Children's Hospital,
· Baylor College of Medicine,
· University of Rochester
This study examines the effectiveness of nirsevimab, a monoclonal antibody, in preventing RSV-related hospitalizations in infants during their first RSV season. Conducted from October 2023 …
Ask aRCie
What U.S. Obstetricians Need to Know About Respiratory Syncytial Virus
This review article discusses two preventive option for the prevention of RSV in infants: a maternal vaccine and a monoclonal antibody for infants. The FDA …
Maternal Respiratory Syncytial Virus Vaccination and Receipt of Respiratory Syncytial Virus Antibody (Nirsevimab) by Infants Aged <8 Months - United States, April 2024
This article is about a study on RSV vaccination for pregnant women and their babies in the U.S. It describes how RSV is a common …
Nirsevimab Effectiveness Against Medically Attended Respiratory Syncytial Virus Illness and Hospitalization Among Alaska Native Children - Yukon-Kuskokwim Delta Region, Alaska, October 2023-June 2024
This report looks at a study on the effectiveness of nirsevimab in preventing respiratory syncytial virus (RSV) illness and hospitalization among Alaska Native children in …
Multiple Questions About Protection From Respiratory Syncytial Virus
2024
· University of Pennsylvania
This article, written by Stanley A. Plotkin, is about protecting people from respiratory syncytial virus (RSV). It describes key questions about protecting against respiratory syncytial …
Nirsevimab: Alleviating the Burden Of RSV Morbidity in Young Children
2024
· Duke-NUS Medical School,
· KK Women's & Children's Hospital,
· University of New South Wales,
· Macquarie University,
· National Centre for Immunisation Research and Surveillance (NCIRS)
This article reviews the real-world data that supports the effectiveness of nirsevimab, a monoclonal antibody that helps protect young children from RSV. Studies have demonstrated …
Nirsevimab and Abrysvo Update for the 2024-2025 Respiratory Season
2024
· Ohio Department of Health
This webpage provides an update on both infant nirsevimab (Beyfortus®) and maternal RSVpreF (Abrysvo™) administration and planning considerations. Infants can be protected against RSV through …
Immunization for Respiratory Syncytial Virus-Promises and Pitfalls
This editorial discusses the potential benefits and challenges of vaccines for the respiratory syncytial virus (RSV). It explains how RSV affects children and older adults, …
Pricey or Priceless: Cost-Effectiveness of Respiratory Syncytial Virus (RSV) Prevention in Infants
2024
· University of Antwerp
This comment discusses the cost-effectiveness of preventing RSV in infants. It compares different strategies, like using monoclonal antibodies (nirsevimab) and a maternal vaccine (MV). It …
Introduction to This JPIDS Supplement: All Infant Protection Against Serious RSV Disease
This article describes the challenges and advancements in protecting infants from serious RSV disease. It highlights the unpredictability of RSV, especially during the COVID-19 pandemic, …